Update on Aplaviroc: An HIV Entry Inhibitor Targeting CCR5 by unknown
BioMed Central
Page 1 of 1
(page number not for citation purposes)
Retrovirology
Open AccessOral presentation
Update on Aplaviroc: An HIV Entry Inhibitor Targeting CCR5
James F Demarest*‡ and the Aplaviroc Project Team
Address: Duke University AIDS Center, Durham, North Carolina, USA
* Corresponding author    ‡Presenting author    
Aplaviroc (873140) is a novel spirodiketopiperazine
CCR5 antagonist that binds specifically to human CCR5
and allosterically inhibits HIV entry. Aplaviroc has exhib-
ited potent in vivo antiviral activity (1.66 log decrease in
viral load at nadir) following 10 days of monotherapy. In
vitro studies of antiviral activity demonstrate that aplavi-
roc is active against HIV isolates from a variety of clades as
well as those resistant to current HIV therapies targeting
RT, PR, and gp41. In vitro studies suggest prolonged CCR5
receptor occupancy (RO) by aplaviroc with an offset half-
life of >100 hours. In vivo studies following short term
aplaviroc administration using CCR5-specific mAb dem-
onstrate substantial and prolonged CCR5 RO (>50%) by
aplaviroc, when plasma drug levels were undetectable,
observed for approximately 5 days.
In the 10 day monotherapy study of aplaviroc in HIV+
subjects, one subject whose virus was R5-tropic at baseline
and day 5 showed that R5X4-tropic (dual/mixed) virus
was present at Day 10. Subsequent analysis revealed rever-
sion to an R5-tropic only phenotype by day 24, with no
decrease in sensitivity to aplaviroc (Fold IC50). The
change in tropism at the population level observed on day
10 was the result of the emergence of pre-existing dual-
tropic virus(-es) that were below the limits of detection on
day 1. Viruses present in a subject's quasispecies that are
below the limits of detection with currently available tro-
pism assays may become detectable following mono-
therapy with a CCR5 antagonist; however, whether
similar changes may occur on combination therapy with
a CCR5 antagonist remains to be determined.
Aplaviroc has demonstrated potent anti-HIV activity in
vitro and in vivo. Furthermore, aplaviroc exhibits a
unique allosteric interaction with CCR5 and demon-
strates prolonged receptor occupancy. CCR5 antagonists
show promise for inhibiting entry of CCR5-using viruses
in the clinical setting.
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